Poly(Thioketal Urethane) Autograft Extenders in an Intertransverse Process Model of Bone Formation
Publication: Tissue Engineering Part A
Volume 25, Issue Number 13-14
Abstract
Iliac crest autograft (AG) is the gold standard for bone grafting. Due to the limited supply of autograft, synthetic materials such as ceramics and polymers have been proposed as AG extenders to minimize the volume of AG required for induction of new bone formation. However, the feasibility of reactive polymers for use as settable AG extenders has not been previously investigated. In this study, a reactive oxygen species-degradable poly(thioketal urethane) (PTKUR) was evaluated as a settable AG extender. AG was anticipated to enhance infiltration of cells into the defect and induce new bone formation. Histological analysis of a preliminary study in a rat femoral segmental defect model showed that cells infiltrated PTKUR/AG implants at 4 weeks. In a second experiment, implantation into an intertransverse process model of bone formation showed bone remodeling from the superior and inferior transverse processes. Histological analysis combining data from stains and fluorochrome injections showed lamellar bone formation ongoing near the base of the transverse processes after 8 weeks. Similar findings were observed for a second group, in which 35% of the AG was replaced with calcium phosphate granules. These observations highlight the potential of PTKUR for use as a settable AG extender.
Impact Statement
The development of autograft extenders is a significant clinical need in bone tissue engineering. We report new settable poly(thioketal urethane)-based autograft extenders that have bone-like mechanical properties and handling properties comparable to calcium phosphate bone cements. These settable autograft extenders remodeled to form new bone in a biologically stringent intertransverse process model of bone formation that does not heal when treated with calcium phosphate bone void fillers or cements alone. This is the first study to report settable autograft extenders with bone-like strength and handling properties comparable to ceramic bone cements, which have the potential to improve treatment of bone fractures and other orthopedic conditions.
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Greenwald A.S., Boden S.D., Goldberg V.M., Khan Y., Laurencin C.T., and Rosier R.N. Bone-graft substitutes: facts, fictions, and applications. J Bone Joint Surg 83-A, S98, 2001.
2. Boden S.D. Biology of lumbar spine fusion and use of bone graft substitutes: present, future, and next generation. Tissue Eng 6, 383, 2000.
3. Boden S.D. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine (Phila Pa 1976) 27, S26, 2002.
4. Dumic-Cule I., Pecina M., Jelic M., et al. Biological aspects of segmental bone defects management. Int Orthop 39, 1005, 2015.
5. Rogers G.F., and Greene A.K. Autogenous bone graft: basic science and clinical implications. J Craniofac Surg 23, 323, 2012.
6. Burkus J.K., Heim S.E., Gornet M.F., and Zdeblick T.A. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. J Spinal Disord Tech 16, 113, 2003.
7. Barnes B., Boden S.D., Louis-Ugbo J., et al. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates. Spine (Phila Pa 1976) 30, 1127, 2005.
8. McKay W.F., Peckham S.M., and Badura J.M. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int Orthop 31, 729, 2007.
9. Talley A.D., Kalpakci K.N., Shimko D.A., Zienkiewicz K.J., Cochran D.L., and Guelcher S.A. Effects of recombinant human bone morphogenetic protein-2 dose and ceramic composition on new bone formation and space maintenance in a canine mandibular ridge saddle defect model. Tissue Eng Part A 22, 469, 2016.
10. Carragee E.J., Ghanayem A.J., Weiner B.K., Rothman D.J., and Bono C.M. A challenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factors. Spine J 11, 463, 2011.
11. Carragee E.J., Hurwitz E.L., and Weiner B.K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11, 471, 2011.
12. Lewandrowski K.-U., Hile D.D., Thompson B.M., Wise D.L., Tomford W.W., and Trantolo D.J. Quantitative measures of osteoinductivity of a porous poly (propylene fumarate) bone graft extender. Tissue Eng 9, 85, 2003.
13. Ryf C., Goldhahn S., Radziejowski M., Blauth M., and Hanson B. A new injectable brushite cement: first results in distal radius and proximal tibia fractures. Eur J Trauma Emerg Surg 35, 389, 2009.
14. Bohner M. Design of ceramic-based cements and putties for bone graft substitution. Eur Cell Mater 20, 1, 2010.
15. Kanter A.S., Gandhoke G.S., Welch W.C., Arnold P.M., Cheng J.S., and Okonkwo D.O. A prospective, multi-center clinical and radiographic outcomes evaluation of ChronOS strip for lumbar spine fusion. J Clin Neurosci 25, 36, 2016.
16. Dai L.-Y., and Jiang L.-S. Single-level instrumented posterolateral fusion of lumbar spine with β-tricalcium phosphate versus autograft: a prospective, randomized study with 3-year follow-up. Spine (Phila Pa 1976) 33, 1299, 2008.
17. Lee J.H., Chang B.S., Jeung U.O., Park K.W., Kim M.S., and Lee C.K. The first clinical trial of beta-calcium pyrophosphate as a novel bone graft extender in instrumented posterolateral lumbar fusion. Clin Orthop Surg 3, 238, 2011.
18. Lee J.H., Hwang C.J., Song B.W., Koo K.H., Chang B.S., and Lee C.K. A prospective consecutive study of instrumented posterolateral lumbar fusion using synthetic hydroxyapatite (Bongros®‐HA) as a bone graft extender. J Biomed Mater Res A 90, 804, 2009.
19. Lerner T., Bullmann V., Schulte T.L., Schneider M., and Liljenqvist U. A level-1 pilot study to evaluate of ultraporous β-tricalcium phosphate as a graft extender in the posterior correction of adolescent idiopathic scoliosis. Eur Spine J 18, 170, 2009.
20. Linovitz R.J., and Peppers T.A. Use of an advanced formulation of β-tricalcium phosphate as a bone extender in interbody lumbar fusion. Orthopedics 25, S585, 2002.
21. Smucker J.D., Petersen E.B., and Fredericks D.C. Assessment of MASTERGRAFT PUTTY as a graft extender in a rabbit posterolateral fusion model. Spine (Phila Pa 1976) 37, 1017, 2012.
22. Chen W.-J., Tsai T.-T., Chen L.-H., et al. The fusion rate of calcium sulfate with local autograft bone compared with autologous iliac bone graft for instrumented short-segment spinal fusion. Spine (Phila Pa 1976) 30, 2293, 2005.
23. Gunzburg R., and Szpalski M. Use of a novel β-tricalcium phosphate-based bone void filler as a graft extender in spinal fusion surgeries. Orthopedics 25, S591, 2002.
24. Kanayama M., Hashimoto T., Shigenobu K., Oha F., Ishida T., and Yamane S. Pitfalls of anterior cervical fusion using titanium mesh and local autograft. J Spinal Disord Tech 16, 513, 2003.
25. von Arx T., and Kurt B. Implant placement and simultaneous ridge augmentation using autogenous bone and a micro titanium mesh: a prospective clinical study with 20 implants. Clin Oral Implants Res 10, 24, 1999.
26. von Arx T., Cochran D.L., Hermann J.S., Schenk R.K., and Buser D. Lateral ridge augmentation using different bone fillers and barrier membrane application. A histologic and histomorphometric pilot study in the canine mandible. Clin Oral Implants Res 12, 260, 2001.
27. McAllister B.S., and Haghighat K. Bone augmentation techniques. J Periodontol 78, 377, 2007.
28. McEnery M.A., Lu S., Gupta M.K., et al. Oxidatively degradable poly(thioketal urethane)/ceramic composite bone cements with bone-like strength. RSC Adv 6, 109414, 2016.
29. Martin J.R., Gupta M.K., Page J.M., et al. A porous tissue engineering scaffold selectively degraded by cell-generated reactive oxygen species. Biomaterials 35, 3766, 2014.
30. Martin J.R., Nelson C.E., Gupta M.K., et al. Local delivery of PHD2 siRNA from ROS-degradable scaffolds to promote diabetic wound healing. Adv Healthc Mater 5, 2751, 2016.
31. Patil P., Martin J.R., Sarett S.M., et al. Porcine ischemic wound healing model for preclinical testing of degradable biomaterials. Tissue Eng Part C Methods 23, 754, 2017.
32. Hile D.D., Kandziora F., Lewandrowski K.-U., Doherty S.A., Kowaleski M.P., and Trantolo D.J. A poly(propylene glycol-co-fumaric acid) based bone graft extender for lumbar spinal fusion: in vivo assessment in a rabbit model. Eur Spine J 15, 936, 2006.
33. Walsh W.R., Oliver R.A., Gage G., et al. Application of resorbable poly (lactide-co-glycolide) with entangled hyaluronic acid as an autograft extender for posterolateral intertransverse lumbar fusion in rabbits. Tissue Eng Part A 17, 213, 2011.
34. Boden S., Schimandle J., and Hutton W. The use of osteoinductive growth factor for lumbar spine fusion. Part II: study of dose, carrier, and species. Spine 24, 2633, 1995.
35. Smucker J.D., Petersen E.B., Nepola J.V., and Fredericks D.C. Assessment of MASTERGRAFT® STRIP with bone marrow aspirate as a graft extender in a rabbit posterolateral fusion model. Iowa Orthop J 32, 61, 2012.
36. Hafeman A.E., Li B., Yoshii T., Zienkiewicz K., Davidson J.M., and Guelcher S.A. Injectable biodegradable polyurethane scaffolds with release of platelet-derived growth factor for tissue repair and regeneration. Pharm Res 25, 2387, 2008.
37. Guelcher S.A., Srinivasan A., Dumas J.E., Didier J.E., McBride S., and Hollinger J.O. Synthesis, mechanical properties, biocompatibility, and biodegradation of polyurethane networks from lysine polyisocyanates. Biomaterials 29, 1762, 2008.
38. Hafeman A.E., Zienkiewicz K.J., Zachman A.L., et al. Characterization of the degradation mechanisms of lysine-derived aliphatic poly(ester urethane) scaffolds. Biomaterials 32, 419, 2011.
39. Harmata A.J., Uppuganti S., Granke M., Guelcher S.A., and Nyman J.S. Compressive fatigue and fracture toughness behavior of injectable, settable bone cements. J Mech Behav Biomed Mater 51, 345, 2015.
40. Dumas J.E., Prieto E.M., Zienkiewicz K.J., et al. Balancing the rates of new bone formation and polymer degradation enhances healing of weight-bearing allograft/polyurethane composites in rabbit femoral defects. Tissue Eng Part A 20, 115, 2014.
41. Lu S., McGough M.A.P., Shiels S.M., et al. Settable polymer/ceramic composite bone grafts stabilize weight-bearing tibial plateau slot defects and integrate with host bone in an ovine model. Biomaterials 179, 29, 2018.
42. Kirkeby O.J., Nordsletten L., and Skjeldal S. Healing of cortical bone grafts in athymic rats. Acta Orthop Scand 63, 318, 1992.
43. Chesmel K.D., Branger J., Wertheim H., and Scarborough N. Healing response to various forms of human demineralized bone matrix in athymic rat cranial defects. J Oral Maxillofac Surg 56, 857, 1998.
44. Festing M.F.W. Athymic nude rats. In: Gershwin M.E., and Merchant B., eds. Immunologic Defects in Laboratory Animals 1. Boston, MA: Springer US, 1981, p. 267.
45. Pearce A.I., Richards R.G., Milz S., Schneider E., and Pearce S.G. Animal models for implant biomaterial research in bone: a review. Eur Cell Mater 13, 1, 2007.
46. Guelcher S.A., Brown K.V., Li B., et al. Dual-purpose bone grafts improve healing and reduce infection. J Orthop Trauma 25, 477, 2011.
47. Brown K.V., Li B., Guda T., Perrien D.S., Guelcher S.A., and Wenke J.C. Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release. Tissue Eng Part A 17, 1735, 2011.
48. Guo X., Lee K.M., Law L.P., Chow H.K., Rosier R., and Cheng C.Y. Recombinant human bone morphogenetic protein-4 (rhBMP-4) enhanced posterior spinal fusion without decortication. J Orthop Res 20, 740, 2002.
49. Rathbone C.R., Guda T., Singleton B.M., et al. Effect of cell‐seeded hydroxyapatite scaffolds on rabbit radius bone regeneration. J Biomed Mater Res A 102, 1458, 2014.
50. Page J.M., Prieto E.M., Dumas J.E., et al. Biocompatibility and chemical reaction kinetics of injectable, settable polyurethane/allograft bone biocomposites. Acta Biomater 8, 4405, 2012.
51. Guo R., Ward C.L., Davidson J.M., Duvall C.L., Wenke J.C., and Guelcher S.A. A transient cell-shielding method for viable MSC delivery within hydrophobic scaffolds polymerized in situ. Biomaterials 54, 21, 2015.
52. Talley A.D., McEnery M.A., Kalpakci K.N., Zienkiewicz K.J., Shimko D.A., and Guelcher S.A. Remodeling of injectable, low-viscosity polymer/ceramic bone grafts in a sheep femoral defect model. J Biomed Mater Res B Appl Biomater 105, 2333, 2017.
53. Guelcher S.A., Patel V., Gallagher K.M., et al. Synthesis and in vitro biocompatibility of injectable polyurethane foam scaffolds. Tissue Eng 12, 1247, 2006.
54. Wolfram U., and Schwiedrzik J. Post-yield and failure properties of cortical bone. Bonekey Rep 5, 829, 2016.
55. Weiner S., Traub W., and Wagner H.D. Lamellar bone: structure–function relations. J Struct Biol 126, 241, 1999.
56. Fulzele K., Krause D.S., Panaroni C., et al. Myelopoiesis is regulated by osteocytes through Gsα-dependent signaling. Blood 121, 930, 2013.
57. Miron R.J., Gruber R., Hedbom E., et al. Impact of bone harvesting techniques on cell viability and the release of growth factors of autografts. Clin Implant Dent Relat Res 15, 481, 2013.
58. Bonewald L.F. The amazing osteocyte. J Bone Miner Res 26, 229, 2011.
59. Brolese E., Buser D., Kuchler U., Schaller B., and Gruber R. Human bone chips release of sclerostin and FGF-23 into the culture medium: an in vitro pilot study. Clin Oral Implants Res 26, 1211, 2015.
60. Reid J.J., Johnson J.S., and Wang J.C. Challenges to bone formation in spinal fusion. J Biomech 44, 213, 2011.
61. Martin G.J., Boden S.D., Marone M.A., Marone M.A., and Moskovitz P.A. Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J Spinal Disord 12, 179, 1999.
62. Duan R., Barbieri D., Luo X., et al. Variation of the bone forming ability with the physicochemical properties of calcium phosphate bone substitutes. Biomater Sci 6, 136, 2017.
63. Epstein N.E. Efficacy of different bone volume expanders for augmenting lumbar fusions. Surg Neurol 69, 16, 2008.
64. Kaiser M.G., Groff M.W., Watters W.C. III et al., Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 16: bone graft extenders and substitutes as an adjunct for lumbar fusion. J Neurosurg Spine 21, 106, 2014.
65. Fillingham Y.A., Lenart B.A., and Gitelis S. Function after injection of benign bone lesions with a bioceramic. Clin Orthop Relat Res 470, 2014, 2012.
66. Boden S.D., Schimandle J.H., Hutton W.C., and Chen M.I. The use of an osteoinductive growth factor for lumbar spinal fusion: part I. Spine (Phila Pa 1976) 20, 2626, 1995.
67. Sanz M., and Vignoletti F. Key aspects on the use of bone substitutes for bone regeneration of edentulous ridges. Dent Mater 31, 640, 2015.
68. Shiels S.M., Talley A.D., McGough M.A.P., et al. Injectable and compression-resistant low-viscosity polymer/ceramic composite carriers for rhBMP-2 in a rabbit model of posterolateral fusion: a pilot study. J Orthop Surg Res 12, 107, 2017.
Information & Authors
Information
Published In
Copyright
Copyright 2019, Mary Ann Liebert, Inc., publishers.
History
Published online: 17 July 2019
Published in print: July 2019
Published ahead of print: 9 January 2019
Published ahead of production: 6 November 2018
Accepted: 26 October 2018
Received: 6 August 2018
Topics
Authors
Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.